Mon, Jan 26, 2015, 6:53 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jd9919 jd9919 Mar 14, 2013 3:05 PM Flag

    Analyst remarks

    Greg Wade, Wedbush (3/11/13) "OncoGeneX Pharmaceuticals Inc. reported Q4/12 earnings per share of ($0.28) based on timing of collaboration revenue from Teva Pharmaceutical Industries Ltd., ending the year with $75.7M in cash. . .the key catalyst for OncoGeneX shares remains data from the phase 3 Synergy trial of OGX-011 (custirsen) in the H1/14 time frame. . .we reiterate our Outperform rating."

    Douglas Loe, Byron Capital Markets (3/8/13) "There is no change in our valuation or investment theses or positive view on the medical potential of OncoGeneX Pharmaceuticals Inc.'s OGX-011 in castrate resistant prostate cancer, with OGX-427 providing future upside to our forecasts; we maintain our Buy rating and $30.50 target. . .the company continues to drive clinical programs for both OGX-011 and OGX-427 in what is among the most robust clinical pipelines in our coverage universe."

    Philippa Flint, Bloom Burton & Co. (3/8/13) "We continue to rate OncoGenex Pharmaceuticals Inc. shares positively as we believe the company's shares are attractively valued for risk-tolerant investors. Pivotal phase 3 data is expected around year-end for custirsen in first-line prostate cancer. . .we are encouraged by the survival data seen in phase 2. . .and recommend investors buy shares at current levels, as we expect them to gain in value in H2/13 as we approach phase 3 data readout."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.11+0.02(+0.96%)Jan 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.